Amer Bio Medica
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- $1.26 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Amer Bio Medica had its IPO on 1997-12-24 under the ticker symbol ABMC.
The company operates in the Healthcare sector and Diagnostics & Research industry. Amer Bio Medica has a staff strength of 32 employees.
Shares of Amer Bio Medica opened at $0.02 at the start of the last trading session i.e. 2023-03-20.
The stocks traded within a range of $0.01 - $0.02, and closed at $0.02.
This is a -19% slip from the previous day's closing price.
A total volume of 110,685 shares were traded at the close of the day’s session.
In the last one week, shares of Amer Bio Medica have increased by +62%.
Amer Bio Medica's Key Ratios
Amer Bio Medica has a market cap of $553132, indicating a price to book ratio of 0 and a price to sales ratio of 0.3833.
In the last 12-months Amer Bio Medica’s revenue was $1.26 million with a gross profit of $548000 and an EBITDA of $-1109000. The EBITDA ratio measures Amer Bio Medica's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amer Bio Medica’s operating margin was -92.59% while its return on assets stood at -42.08% with a return of equity of 0%.
In Q3, Amer Bio Medica’s quarterly earnings growth was a positive 0% while revenue growth was a negative 66%.
Amer Bio Medica’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amer Bio Medica’s profitability.
Amer Bio Medica stock is trading at a EV to sales ratio of 1.666 and a EV to EBITDA ratio of -1.8009. Its price to sales ratio in the trailing 12-months stood at 0.3833.
Amer Bio Medica stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.18 million
- Total Liabilities
- $3.19 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Amer Bio Medica ended 2023 with $1.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.18 million while shareholder equity stood at $-2022000.00.
Amer Bio Medica ended 2023 with $0 in deferred long-term liabilities, $3.19 million in other current liabilities, 481000.00 in common stock, $-24906000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10000.00 and cash and short-term investments were $10000.00. The company’s total short-term debt was $1,608,000 while long-term debt stood at $0.
Amer Bio Medica’s total current assets stands at $670000.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $241000.00 compared to accounts payable of $950000.00 and inventory worth $380000.00.
In 2023, Amer Bio Medica's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Amer Bio Medica paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Amer Bio Medica stock is currently trading at $0.02 per share. It touched a 52-week high of $0.04 and a 52-week low of $0.04. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.01 and 200-day moving average was $0.02 The short ratio stood at 0.09 indicating a short percent outstanding of 0%.
Around 3192.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Amer Bio Medica
Similar Industry Stocks (Diagnostics & Research)
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to non-affiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.